Literature DB >> 29300395

Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?

Wolfram C M Dempke1,2, Klaus Fenchel3.   

Abstract

Entities:  

Year:  2017        PMID： 29300395      PMCID： PMC5750166          DOI： 10.21037/tlcr.2017.06.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

Review 3.  Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.

Authors:  Harun Patel; Rahul Pawara; Azim Ansari; Sanjay Surana
Journal:  Eur J Med Chem       Date:  2017-05-11       Impact factor: 6.514

Review 4.  Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

Authors:  Oscar Juan; Sanjay Popat
Journal:  Ther Adv Med Oncol       Date:  2017-01-30       Impact factor: 8.168

5.  Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Authors:  Chee Khoon Lee; Yi-Long Wu; Pei Ni Ding; Sarah J Lord; Akira Inoue; Caicun Zhou; Tetsuya Mitsudomi; Rafael Rosell; Nick Pavlakis; Matthew Links; Val Gebski; Richard J Gralla; James Chih-Hsin Yang
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

6.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

Review 7.  Targeted Therapy for NSCLC--A Double-edged Sword?

Authors:  Wolfram C M Dempke
Journal:  Anticancer Res       Date:  2015-05       Impact factor: 2.480

Review 8.  Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.

Authors:  Kaixian Zhang; Qianqian Yuan
Journal:  J Cancer Res Ther       Date:  2016-12       Impact factor: 1.805

9.  Overall survival in non-small cell lung cancer-what is clinically meaningful?

Authors:  Klaus Fenchel; Ludger Sellmann; Wolfram C M Dempke
Journal:  Transl Lung Cancer Res       Date:  2016-02

10.  A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.

Authors:  J J Yang; Q Zhou; H H Yan; X C Zhang; H J Chen; H Y Tu; Z Wang; C R Xu; J Su; B C Wang; B Y Jiang; X Y Bai; W Z Zhong; X N Yang; Y L Wu
Journal:  Br J Cancer       Date:  2017-01-19       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.